Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hemoglobin Clear all

Conditions: Iron Deficiency
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 1,820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: Pociredir; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 8
States / cities: Little Rock, Arkansas • Los Angeles, California • Baton Rouge, Louisiana + 5 more

Conditions: Blood Loss
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Postpartum Hemorrhage
Interventions: Oxytocin Infusion; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pain Crisis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 90 Years
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Type 2 Diabetes
Interventions: HM11260C, liraglutide, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: CA, California

Conditions: Complications of Pregnancy, Childbirth and the Puerperium
Interventions: Masimo Rainbow Sensor; Device
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: End Stage Renal Disease, Anemia
Interventions: Roxadustat, Epoetin Alfa, Placebo; Drug · Other
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more

Conditions: Anemia
Interventions: methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 78
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more

Conditions: Anemia
Interventions: INVSENSOR00026 (Pulse CO-Oximeter and sensor); Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lomita, California

Conditions: Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions: Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen; Drug · Other
Lead sponsor: St. Louis University; Other
Eligibility: 5 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hemoglobinuria, Paroxysmal
Interventions: Eculizumab; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 1 Year to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Surgery, Hemoglobin
Interventions: Pulse CO-Oximetry Technology, Blood draw; Device · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: β-thalassemia Major
Interventions: LentiGlobin BB305 Drug Product; Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois + 1 more

Conditions: Anemia, Fluid Management
Interventions: Not listed
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 9
States / cities: Pine Bluff, Arkansas • Mountain View, California • Lauderdale Lakes, Florida + 6 more

Conditions: Pregnancy
Interventions: Néevo®/ NéevoDHA®; Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Corpus Christi, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Peer Mentoring; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Total Joint Arthroplasty
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Fracture of Posterior Wall of Acetabulum
Interventions: Tranexamic Acid, Normal saline; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type 2 Diabetes
Interventions: vitamin D3, cholecalciferol, Inactive comparator; Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 19 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Anemia in Pregnancy
Interventions: Masimo spot hemoglobin non-invasive monitor; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 34
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Search by objective public record fields.

Iron Replacement in Blood Donors

Open-Label Extension Study to Pioneer Study 6058-SCD-101

Comparison of Three Methods of Hemoglobin Monitoring

Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.

Natural History of Sickle Cell Disease

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Non-Invasive Hemoglobin Monitoring of Women Undergoing Cesarean Delivery

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation of INVSENSOR00026

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

Assessment of Stability of Mail-in Capillary Hemoglobin A1c Test Kit

Accuracy of Pulse CO-Oximetry Technology in Characterizing Noninvasive SpHb

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

Comparison of Pulse Hemoglobin and Pleth Variability Index

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)

Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control

Non-invasive Hemoglobin Monitoring in Outpatient Total Joint Arthroplasty

Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit

The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults

Non-invasive Spot Hemoglobin Measurement in the Outpatient Obstetric Clinic

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus